Cancer vax developer Kite lands $15M

 

LA-based Kite Pharma, a fledgling biotech that has set out to develop new cancer vaccine therapies, has raised $15 million in Series A venture cash. The company will use the funding to support development of its preclinical pipeline and work on its Phase I therapeutic vaccine for hepatocellular cancer. Kite release

Suggested Articles

Merck
Vaccines

Merck makes history with world's first Ebola shot approval

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

by Eric Sagonowsky
Vaccines

Cosette to add liquids to its mix with deal for 2nd plant

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

by Eric Palmer
Malaria Mosquito
Vaccines

Takeda's dengue shot 80% effective in massive phase 3 test

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.

by Eric Sagonowsky